Other substances

Rosuvastatin

A statin.

Phase of research

Potential treatment - clinical evidence

How it helps

Other treatment

Drug status

Used to treat other disease

2
 Supporting references
0
 Contradictory references
3
 AI-suggested references
2
 Clinical trials

General information

Rosuvastatin counters lipidemia and displays antineoplastic activities (NCIt).

Rosuvastatin on DrugBank
Rosuvastatin on PubChem
Rosuvastatin on Wikipedia

Marketed as

ASTENDE; CIRANTAN; CRESADEX; CRESTOR; EZALLOR SPRINKLE; PROVISACOR; RAZEL; ROSEDEX; ROSIMOL; ROSUMED; ROSUSTATIN; ROSUVAS; ROSUVAST; ROSVEL; ROVARTAL; ROSUVASTATIN; SIMESTAT; SINLIP; VISACOR; VIVACOR

 

Structure image - Rosuvastatin

CC(C)C1=NC(=NC(=C1/C=C/[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C

Supporting references

Link Tested on Impact factor Notes Publication date
In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19
Patients 21.57

A retrospective cohort study of in-hospital statin use among COVID-19 patients. Lower risk of all-cause mortality. Lower use of invasive mechanical ventilation, ARDS prevalence and ICU admission. Possible due to inflammatory response amelioration. Dosage - daily equivalent dose of statin, median 20 mg. Endpoints - 28-day all-cause mortality; ICU admission; use of invasive mechanical ventilation; ARDS incidence. Sample size 190 patients (1,219 statins + 12,762 control).

 Aug/04/2020
Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial
ARDS Small molecule Randomized controlled open trial 		Pneumonia patients

The combined treatment using colchicine, emtricitabine, tenofovir, and rosuvastatin resulted in lower mortality and invasive mechanical ventilation need compared to control. Sample size: (ITT) 159 + 161 control. Dosage: 40 mg daily for 14 days. Main outcome: 28-day mortality.

 Dec/20/2021

AI-suggested references

Link Publication date
Central blood pressure lowering effect of telmisartan-rosuvastatin single-pill combination in hypertensive patients combined with dyslipidemia: A pilot study
Oct/18/2021
Statins and the COVID-19 main protease: in silico evidence on direct interaction
Apr/25/2020
Protective effect of Rosuvastatin on Azithromycin induced cardiotoxicity in a rat model
Mar/04/2022

Clinical trials

ID Title Status Phase Start date Completion date
NCT04472611 Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial Recruiting Phase 3 Oct/30/2020 Aug/01/2022
  • Alternative id - 2000027950
  • Interventions - Drug: Standard of Care (SOC) and Colchicine+Rosuvastatin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Bridgeport Hospital, Bridgeport, Connecticut, United States|Greenwich Hospital, Greenwich, Connecticut, United States|Yale New Haven Hosptial System, New Haven, Connecticut, United States|Lawrence & Memorial Hospital, New London, Connecticut, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 466
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - COVID 19 Severity
NCT04359095 Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia Completed Phase 2|Phase 3 Aug/18/2020 Jun/30/2021
  • Alternative id - 76968
  • Interventions - Drug: Emtricitabine/tenofovir|Drug: Colchicine Pill|Drug: Rosuvastatin|Other: Standard treatment
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Clinica santa Maria del lago, Bogota, DC, Colombia|Clínica Reina Sofía, Bogotá, Colombia|Fundacion Cardio Infantil, Bogotá, Colombia|Hospital Universitario San Ignacio, Bogotá, Colombia|Clinica Universitaria Colombia, Bogotá, Colombia|Hospital Universitario Nacional de Colombia, Bogotá, Colombia
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 650
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Mortality|Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection|Time to death|Number of Participants that are transferred to the Intensive Care Unit (ICU)|Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.|Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray|Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection
Export (.csv)